Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18463857 | 0.77 | CRHBP (0.36) | ALDH1A1LMNAMEN1KMT2ATSHR | |
| SCHEMBL25530567 | 0.76 | TSHR (0.42) | LMNATSHR | |
| SCHEMBL17886005 | 0.75 | AOC3 (0.44) | ALDH1A1LMNAMEN1KMT2ATSHR | |
| SCHEMBL18463675 | 0.74 | CRHBP (0.30) | CRHBPCRHR2 | |
| SCHEMBL13981951 | 0.71 | HRH3 (0.52) | ALDH1A1TSHRCRHBPCRHR2 | |
| SCHEMBL18463964 | 0.70 | RIPK1 (0.36) | CRHBPCRHR2 | |
| SCHEMBL18463851 | 0.69 | CRHBP (0.39) | MAPTMEN1KMT2ACRHBPCRHR2 | |
| SCHEMBL12091895 | 0.68 | ESR1 (0.54) | GAAALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL11826492 | 0.66 | CRHBP (0.48) | GAAALDH1A1LMNAMAPTNPSR1 | |
| SCHEMBL13995424 | 0.66 | CHRM2 (0.44) | GAAALDH1A1LMNAMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10351527-B2 | Binding function 3 (BF3) site compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-07-16 | — | — | US | disclosed |
| US-20170029372-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351527-B2 | Binding function 3 (BF3) site compounds as therapeutics and methods for their use | KLK3, SHBG, ACP3 | GAA 3173/4885ALDH1A1 2387/4885LMNA 3294/4885 |
| US-20170029372-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | KLK3, SHBG, ACP3 | GAA 3173/4885ALDH1A1 2387/4885LMNA 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.